Beta-2 adrenergic receptor and M3 muscarinic receptor — Drug Target

All drugs that target Beta-2 adrenergic receptor and M3 muscarinic receptor — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

LABA/LAMA combination bronchodilator · LABA/LAMA combination (Long-Acting Beta-2 Agonist / Long-Acting Muscarinic Antagonist)

Marketed (1)

• Indacaterol and tiotropium · University of Dundee · LABA/LAMA combination bronchodilator · Respiratory
  Indacaterol and tiotropium is a fixed-dose combination of a long-acting beta-2 agonist and a long-acting muscarinic antagonist that work synergistically to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.

Phase 3 pipeline (1)

• CHF 1535 · Chiesi Farmaceutici S.p.A. · LABA/LAMA combination (Long-Acting Beta-2 Agonist / Long-Acting Muscarinic Antagonist) · Respiratory / Pulmonology
  CHF 1535 is a dual bronchodilator that combines a long-acting beta-2 agonist with a long-acting muscarinic antagonist to improve airway function in chronic obstructive pulmonary disease.

Phase 2 pipeline (1)

• CHF 4226 pMDI · Chiesi Farmaceutici S.p.A. · LABA/LAMA combination bronchodilator · Respiratory
  CHF 4226 is an inhaled dual bronchodilator combining a long-acting beta-2 agonist and long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease.